U.S. clinical trial results show Novavax vaccine is safe and …
Jun 14, 2021 · Results from a Phase 3 clinical trial enrolling 29,960 adult volunteers in the United States and Mexico show that the investigational vaccine known as NVX-CoV2373 demonstrated 90.4% efficacy in preventing symptomatic COVID-19 disease.
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Jun 30, 2021 · Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), which consists of 5 μg of a recombinant nanoparticle spike protein plus 50 μg of Matrix-M adjuvant, have shown that a...
Efficacy and Safety of NVX-CoV2373 in Adults in the United States …
Dec 15, 2021 · NVX-CoV2373 was found to be safe and immunogenic in adults 10,11 and provided high vaccine efficacy against severe disease caused by the B.1.351 (beta) variant of concern in a phase 2b trial in...
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein …
Sep 2, 2020 · We report here the findings of the phase 1 part of a randomized, placebo-controlled, phase 1–2 trial that commenced in May 2020 to evaluate the safety and immunogenicity of 5-μg and 25-μg doses...
Immunogenicity and safety of NVX-CoV2373 as a booster: A …
Sep 22, 2023 · Methods: The 2019nCoV-307 study was a phase 3, randomized, observer-blinded trial evaluating immunogenicity and safety of NVX-CoV2373 in previously vaccinated adults aged 18-49 years in the United States (NCT05463068).
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy …
Jun 15, 2021 · Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission.
Phase 3 trial of Novavax investigational COVID-19 vaccine opens
Dec 28, 2020 · The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico.
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID …
In this randomized clinical trial, NVX-CoV2373 was safe, immunogenic, and efficacious in preventing COVID-19, including the predominant Delta variant, in adolescents.
Statement—U.S. Clinical Trial Results Show Novavax Vaccine is …
Jun 14, 2021 · Results from a Phase 3 clinical trial enrolling 15,000 adults in the United Kingdom showed a two-dose regimen of NVX-CoV2373 was highly effective in preventing symptomatic COVID-19 overall and also demonstrated high efficacy against the Alpha variant strain of …
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine …
Sep 8, 2021 · The clinical trial combines Novavax' recombinant protein-based NVX-CoV2373 and NanoFlu™ vaccine candidates and patented saponin-based Matrix-M™ adjuvant in a single formulation (COVID-NanoFlu Combination Vaccine).